Patent directory · USPTO A61K / A61P
Patents matching “combination”
418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12239712
Combination therapy for the treatment of liver disease
granted -
US 12233119
Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
granted -
US 12233104
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
granted -
US 12220420
Combination therapy for cancer treatment
granted -
US 12220389
Combination therapy for the treatment of tinnitus and other medical conditions
granted -
US 12208099
Combination therapies
granted -
US 12201719
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
granted -
US 12186428
Combination taxoid nanoemulsion with immunotherapy in cancer
granted -
US 2025002606
Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
granted -
US 12171765
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted -
US 12168054
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
granted -
US 12161607
Combination of cannabinoids in the treatment of leukemia
granted -
US 12156863
Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
granted -
US 2024390332
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
granted -
US 2024390317
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12128048
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted -
US 12128034
Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
granted -
US 12121288
Combination tumor treatment
granted -
US 12115163
Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
granted -
US 12109197
Combinations of β-lactam compounds and probenecid and uses thereof
granted -
US 12109258
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
granted -
US 12102617
Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent
granted -
US 12090183
Methods of treating solid or lymphatic tumors by combination therapy
granted